<DOC>
	<DOC>NCT01832415</DOC>
	<brief_summary>The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)</brief_summary>
	<brief_title>First Line Ovarian Cancer Treatment - Cohort Study</brief_title>
	<detailed_description>Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients aged 18 years and over, Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in firstline therapy Patients should be informed of the study orally and should not have any objection their data to be processed. Patient participation in a clinical trial Patient nonaffiliated to a social security scheme.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>First line treatment</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>fallopian tube or primary peritoneal</keyword>
</DOC>